The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile
Open accessAbstract
BACKGROUND: Mass vaccination campaigns to prevent coronavirus disease 2019 (Covid-19) are occurring in many countries; estimates of vaccine effectiveness are urgently needed to support decision making. A countrywide mass vaccination campaign with the use of an inactivated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine (CoronaVac) was conducted in Chile starting on February 2, 2021. METHODS: We used a prospective national cohort, including participants 16 years of age or older who were affiliated with the public national health care system, to assess the effectiveness of the inactivated SARS-CoV-2 vaccine with regard to preventing Covid-19 and related hospitalization, admission to the intensive care unit (ICU), and death. We estimated hazard ratios using the extension of the Cox proportional-hazards model, accounting for time-varying vaccination status. We estimated the change in the hazard ratio associated with partial immunization (≥14 days after receipt of the first dose and before receipt of the second dose) and full immunization (≥14 days after receipt of the second dose). Vaccine effectiveness was estimated with adjustment for individual demographic and clinical characteristics. RESULTS: The study was conducted from February 2 through May 1, 2021, and the cohort included approximately 10.2 million persons. Among persons who were fully immunized, the adjusted vaccine effectiveness was 65.9% (95% confidence interval [CI], 65.2 to 66.6) for the prevention of Covid-19 and 87.5% (95% CI, 86.7 to 88.2) for the prevention of hospitalization, 90.3% (95% CI, 89.1 to 91.4) for the prevention of ICU admission, and 86.3% (95% CI, 84.5 to 87.9) for the prevention of Covid-19-related death. CONCLUSIONS: Our results suggest that the inactivated SARS-CoV-2 vaccine effectively prevented Covid-19, including severe disease and death, a finding that is consistent with results of phase 2 trials of the vaccine. (Funded by Agencia Nacional de Investigación y Desarrollo and others.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical characteristics of coronavirus disease 2019 in China
Guan, W.-J., Ni, Z.-Y., Hu, Y., Liang, W.-H., Ou, C.-Q., He, J.-X., Liu, L., Shan, H., Lei, C.-L., Hui, D. S. C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2002032 · Cited by 30,246
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2035389 · Cited by 10,119
An interactive web-based dashboard to track COVID-19 in real time
Dong, E., Du, H., & Gardner, L. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30120-1 · Cited by 10,048
Richardson, S., Hirsch, J. S., Narasimhan, M., Crawford, J. M., McGinn, T., Davidson, K. W., and the Northwell COVID-19 Research Consortium, Barnaby, D. P., Becker, L. B., Chelico, J. D., et al. (2020) · JAMA · doi:10.1001/jama.2020.6775 · Cited by 9,254
Voysey, M., Clemens, S. A. C., Madhi, S. A., Weckx, L. Y., Folegatti, P. M., Aley, P. K., Angus, B., Baillie, V. L., Barnabas, S. L., Bhorat, Q. E., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32661-1 · Cited by 4,616
Wiersinga, W. J., Rhodes, A., Cheng, A. C., Peacock, S. J., & Prescott, H. C. (2020) · JAMA · doi:10.1001/jama.2020.12839 · Cited by 4,609
Estimates of the severity of coronavirus disease 2019: a model-based analysis
Verity, R., Okell, L. C., Dorigatti, I., Winskill, P., Whittaker, C., Imai, N., Cuomo-Dannenburg, G., Thompson, H., Walker, P. G. T., Fu, H., et al. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30243-7 · Cited by 3,660
BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting
Dagan, N., Barda, N., Kepten, E., Miron, O., Perchik, S., Katz, M. A., Hernán, M. A., Lipsitch, M., Reis, B., & Balicer, R. D. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2101765 · Cited by 2,527
Logunov, D. Y., Dolzhikova, I. V., Shcheblyakov, D. V., Tukhvatulin, A. I., Zubkova, O. V., Dzharullaeva, A. S., Kovyrshina, A. V., Lubenets, N. L., Grousova, D. M., Erokhova, A. S., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00234-8 · Cited by 1,747
Cited by
Feikin, D. R., Higdon, M. M., Abu-Raddad, L. J., Andrews, N., Araos, R., Goldberg, Y., Groome, M. J., Huppert, A., O'Brien, K. L., Smith, P. G., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)00152-0 · Cited by 1,237
Tregoning, J. S., Flight, K. E., Higham, S. L., Wang, Z., & Pierce, B. F. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-021-00592-1 · Cited by 1,125
Fiolet, T., Kherabi, Y., MacDonald, C.-J., Ghosn, J., & Peiffer-Smadja, N. (2022) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.10.005 · Cited by 911
Real-world effectiveness of COVID-19 vaccines: a literature review and meta-analysis
Zheng, C., Shao, W., Chen, X., Zhang, B., Wang, G., & Zhang, W. (2022) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2021.11.009 · Cited by 693
Costa Clemens, S. A., Weckx, L., Clemens, R., Almeida Mendes, A. V., Ramos Souza, A., Silveira, M. B. V., da Guarda, S. N. F., de Nobrega, M. M., de Moraes Pinto, M. I., Gonzalez, I. G. S., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)00094-0 · Cited by 435
Pérez-Then, E., Lucas, C., Monteiro, V. S., Miric, M., Brache, V., Cochon, L., Vogels, C. B. F., Malik, A. A., De la Cruz, E., Jorge, A., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01705-6 · Cited by 401
Cheng, S. M. S., Mok, C. K. P., Leung, Y. W. Y., Ng, S. S., Chan, K. C. K., Ko, F. W., Chen, C., Yiu, K., Lam, B. H. S., Lau, E. H. Y., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01704-7 · Cited by 361
McMenamin, M. E., Nealon, J., Lin, Y., Wong, J. Y., Cheung, J. K., Lau, E. H. Y., Wu, P., Leung, G. M., & Cowling, B. J. (2022) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(22)00345-0 · Cited by 360
Ranzani, O. T., Hitchings, M. D. T., Dorion, M., D’Agostini, T. L., de Paula, R. C., de Paula, O. F. P., Villela, E. F. D. M., Torres, M. S. S., de Oliveira, S. B., Schulz, W., et al. (2021) · BMJ · doi:10.1136/bmj.n2015 · Cited by 348
Liu, Q., Qin, C., Liu, M., & Liu, J. (2021) · Infectious Diseases of Poverty · doi:10.1186/s40249-021-00915-3 · Cited by 341
Zeng, G., Wu, Q., Pan, H., Li, M., Yang, J., Wang, L., Wu, Z., Jiang, D., Deng, X., Chu, K., et al. (2022) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(21)00681-2 · Cited by 318
Overview of the Main Anti-SARS-CoV-2 Vaccines: Mechanism of Action, Efficacy and Safety
Mascellino, M. T., Di Timoteo, F., De Angelis, M., & Oliva, A. (2021) · Infection and Drug Resistance · doi:10.2147/idr.s315727 · Cited by 253
Comparison of the immunogenicity of BNT162b2 and CoronaVac COVID ‐19 vaccines in Hong Kong
Mok, C. K. P., Cohen, C. A., Cheng, S. M. S., Chen, C., Kwok, K., Yiu, K., Chan, T., Bull, M., Ling, K. C., Dai, Z., et al. (2022) · Respirology · doi:10.1111/resp.14191 · Cited by 162
“This is consistent with high levels of protection against hospitalization and death in CoronaVac vaccines observed in Chile and Turkey despite lower antibody neutralization titres than BNT162b2.(30,31) In animal models of re-infection, spike-specific CD8 T-cell responses can compensate for inadequate antibody response…”
Cabore, J. W., Karamagi, H. C., Kipruto, H. K., Mungatu, J. K., Asamani, J. A., Droti, B., Titi-ofei, R., Seydi, A. B. W., Kidane, S. N., Balde, T., et al. (2022) · The Lancet Global Health · doi:10.1016/s2214-109x(22)00233-9 · Cited by 108
(2022) · doi:10.1038/s41564-022-01092-1 · Cited by 98
Waning COVID-19 Vaccine Effectiveness for BNT162b2 and CoronaVac in Malaysia: An Observational Study
Suah, J. L., Husin, M., Tok, P. S. K., Tng, B. H., Thevananthan, T., Low, E. V., Appannan, M. R., Muhamad Zin, F., Mohd Zin, S., Yahaya, H., et al. (2022) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2022.03.028 · Cited by 76
Lim, J. M. E., Hang, S. K., Hariharaputran, S., Chia, A., Tan, N., Lee, E. S., Chng, E., Lim, P. L., Young, B. E., Lye, D. C., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100793 · Cited by 73
Metadata
- Authors
- Jara, A., Undurraga, E. A., González, C., Paredes, F., Fontecilla, T., Jara, G., Pizarro, A., Acevedo, J., Leo, K., Leon, F., Sans, C., Leighton, P., Suárez, P., García-Escorza, H., & Araos, R.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-09-02
- Volume
- 385
- Issue
- 10
- Pages
- 875-884
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3179399516
- Cited by
- 866
- References
- 30
- FWCI
- 59.30
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.